It was short and sweet. Focused on the Satipharm product and trying to get as many participants as possible for the clinical study.Jcurve already replied but to confirm they entered into a new 15 mill working capital facility with NAB on the 22/04/22 and renegotiated the 50 mill loan so no repayments until May 2024. I spent a lot more time looking at numbers before something I haven’t got the energy for right now but I remember they had enough money (judging from the last quarterly release and taking into account increased expenses) to keep going until EOFY 22/23.Being optimistic I currently feel they have the potential to break even next year. Hopefully then also increasing revenues further to comfortably repay loans (of course all dependent on the S3 registration).
- Forums
- ASX - By Stock
- CAN
- Interesting cannabis articles and worldwide updates.
Interesting cannabis articles and worldwide updates., page-93
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CAN (ASX) to my watchlist
(20min delay)
|
|||||
Last
6.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $27.12M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
CAN (ASX) Chart |
Day chart unavailable